Concepedia

Pharmacodynamic Marker Modeling

Pharmacodynamic Marker Modeling is a computational or mathematical framework that characterizes the physiological and biochemical effects of therapeutic interventions over time by quantitatively linking drug exposure to downstream biomarker responses within biological systems.

2

Publications

76

Citations

14

Authors

13

Institutions

Publications per year

2017–2026

0

Parents

Publications

2

The scopolamine model as a pharmacodynamic marker in early drug development

Robert Lenz, Jeffrey D. Baker, Charles Locke et al. · Psychopharmacology · 2011 · 57 citations

, , +13

Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer

Gregory R. Pond, William R. Berry, Matthew D. Galsky et al. · Clinical Genitourinary Cancer · 2012 · 19 citations

, , +15

Modelling TKI258 exposure and biomarker response in support of phase I dosing schedule finding

X. Wang, José Saro, Ziewn Wei et al. · Journal of Clinical Oncology · 2008 · 10 citations

, , +16

Reproducibility of the Ribosomal RNA Synthesis Ratio in Sputum and Association with Markers of Mycobacterium tuberculosis Burden

Emmanuel Musisi, Christian Dide-Agossou, Reem Al Mubarak et al. · Microbiology Spectrum · 2021 · 10 citations · Full text

, , +10

1–4 of 2

Authors

14

  1. LE
    Lynne E. Rueter

    Abbott (United Kingdom), United Kingdom

    1 publications · 57 citations

    1

    h-index

  2. CL
    Charles Locke

    Abbott Fund, United States

    1 publications · 57 citations

    1

    h-index

  3. RL
    Robert Lenz

    Amgen (United States), United States

    1 publications · 57 citations

    1

    h-index

  4. GS
    Guru Sonpavde

    Dana-Farber Cancer Institute, United States

    1 publications · 19 citations

    1

    h-index

  5. MS
    Mario Saltarelli

    Abbott Fund, United States

    1 publications · 57 citations

    1

    h-index

1–5 of 14

Institutions

13

  1. United BioSource Corporation (United Kingdom)

    London, United Kingdom

    1 h-index

    1 publications

    57 citations

  2. Abbott (United States)

    Chicago, United States

    1 h-index

    5 publications

    285 citations

  3. Abbott (United Kingdom)

    Maidenhead, United Kingdom

    1 h-index

    1 publications

    57 citations

  4. Novartis (Switzerland)

    Basel, Switzerland

    1 h-index

    1 publications

    57 citations

  5. University of Alabama at Birmingham

    Birmingham, United States

    1 h-index

    1 publications

    19 citations

  6. McMaster University

    Hamilton, Canada

    1 h-index

    1 publications

    19 citations

  7. Takeda (United States)

    Deerfield, United States

    1 h-index

    1 publications

    57 citations

  8. Ontario Clinical Oncology Group

    Hamilton, Canada

    1 h-index

    1 publications

    19 citations

1–8 of 13

Venues

  1. Psychopharmacology

    1 publications · 57 citations

    1

    h-index

  2. Clinical Genitourinary Cancer

    1 publications · 19 citations

    1

    h-index

  3. Journal of Clinical Oncology

    1 publications · 10 citations

  4. Microbiology Spectrum

    1 publications · 10 citations

1–4